Gene delivery vectors with cell type specificity for mesenchymal stem cells
CA 2451577 C · Owner: Vogels, Ronald · Inventors: Vogels, Ronald; Havenga, Menzo Jans Emco; Bout, Abraham
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides novel methods and means for delivering a heterologous nucleic acid of interest to mesenchymal stem cells by providing recombinant adenoviral vectors provided with or having a natural tropism for , mesenchymal stem cells typically in combination with a reduced tropism for other kinds of cells, in particular liver cells. The invention also provides mesenchymal stem cells provided with a heterologous nucleic acid through the use of a recombinant adenoviral vector according to the invention and the use , of such mesenchymal stem cells for the preparation of medicaments for the treatment of multiple sclerosis, rheumatoid arthritis angiogenesis and bone , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 5, 2002 and granted September 11, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 5, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 5, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.